Charles River Laboratories
251 Ballardvale Street
Wilmington
Massachusetts
01887
United States
Tel: 877-274-8371
Website: http://www.criver.com/
About Charles River Laboratories
About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.
With over 11,000 employees within 70 facilities in 18 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2016, revenue increased by 23.3% to $1.68 billion from $1.36 billion in 2015.
At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~70% of the drugs approved by the FDA in 2016.
For more information, please visit www.criver.com.
Equal Employment Opportunity
Charles River Laboratories, Inc. is an Equal Opportunity Employer M/F/Disabled/Vet
488 articles about Charles River Laboratories
-
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
4/22/2024
Charles River Laboratories International, Inc. (NYSE: CRL) today announced it has reached 100 percent renewable electricity across all of its global sites as of the first quarter of 2024, significantly ahead of the original target date.
-
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
4/16/2024
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is launching its Alternative Methods Advancement Project (AMAP), an initiative dedicated to developing alternatives to reduce animal testing.
-
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
4/12/2024
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2024 financial results on Thursday, May 9th, before the market opens.
-
Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
4/11/2024
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI) decision support tool developed in collaboration with Deciphex, an innovator in pathology AI.
-
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
4/9/2024
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd . Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure.
-
Charles River to Perform Plasmid Production for Ship of Theseus
4/4/2024
Charles River Laboratories International, Inc. and Ship of Theseus, a therapeutics company developing degradation-resistant homeobox family biologics, announced a Good Manufacturing Practice- plasmid DNA contract development and manufacturing organization agreement.
-
Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024
4/1/2024
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that its industry-leading team of oncology experts will attend the American Association for Cancer Research (AACR) Annual Meeting.
-
Charles River Laboratories Publishes 2023 Corporate Citizenship Report
3/27/2024
Charles River Laboratories International, Inc. announced the publication of its 2023 Corporate Citizenship Report, which includes progress and results from 2022 and 2023.
-
Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
3/21/2024
Charles River Laboratories International, Inc. (NYSE: CRL) and National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicine),
-
Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration
3/14/2024
Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics , Inc. today announced an AAV9 production program agreement.
-
Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells
2/20/2024
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an agreement with Pluristyx Inc., a leading provider of tools, technologies, and services for the development of cell therapies.
-
Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance
2/14/2024
Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance.
-
Charles River Introduces the First Rapid Animal-Free Bacterial Endotoxin Test
1/29/2024
Building upon its flagship Endosafe ® cartridge technology, Charles River Laboratories International, Inc. (NYSE: CRL) has advanced this innovation one step further and combined it with their recombinant cascade reagent (rCR) to launch the Endosafe ® Trillium™ rCR cartridge offering.
-
Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors
1/24/2024
Charles River Laboratories International, Inc. announced the appointment of Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer, Novartis US, to its Board of Directors.
-
Charles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector Manufacturing
1/16/2024
Charles River Laboratories International, Inc. announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline adeno-associated virus -based gene therapy programs.
-
Charles River Laboratories to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/8/2024
Charles River Laboratories International, Inc. announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th, at 10:30 a.m. PST.
-
Charles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening
12/12/2023
Charles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening.
-
Visgenx and Charles River Announce Expansion of Gene Therapy Manufacturing Alliance
12/7/2023
Visgenx, Inc announced an extension of their contract development and manufacturing organization (CDMO) collaboration with Charles River Laboratories International, Inc., for VGX-0111, a gene therapy being developed by Visgenx for dry age-related macular degeneration (AMD).
-
Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration
11/28/2023
Charles River Laboratories International, Inc. (NYSE: CRL) and Genetic Cures for Kids Inc today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration.
-
Charles River Laboratories to Present at Evercore ISI Investor Conference - November 27, 2023
11/27/2023
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29th, at 9:10 a.m. ET.